Literature DB >> 15111515

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes.

Edmond A Ryan1, Sharleen Imes, Clarissa Wallace.   

Abstract

OBJECTIVE: Type 2 diabetes is associated with defects in insulin secretion and insulin action. Hyperglycemia may aggravate these defects, a feature known as glucose toxicity. Previous studies have shown that acute correction of hyperglycemia in subjects with long-standing type 2 diabetes gives only short-term improvement in glycemic control after discontinuation of insulin. The current study attempts to identify any characteristics of patients with newly diagnosed type 2 diabetes (fasting glucose >11.0 mmol/l) who would have a long-term benefit, in terms of glycemic control, from a brief course of insulin therapy. RESEARCH DESIGN AND METHODS: A total of 16 subjects (52 +/- 2 years old [range 36-64], BMI 30.8 +/- 1.9 kg/m2) with newly diagnosed type 2 diabetes had a 2-3 week course of intensive insulin therapy that was then discontinued.
RESULTS: Fasting glucose fell from 13.3 +/- 0.7 to 7.0 +/- 0.4 mmol/l, and this improvement was maintained at the 1-year follow-up (6.7 +/- 0.3 mmol/l). The insulin area under the curve for the posttreatment oral glucose tolerance test also improved (8,251 +/- 1,880 before therapy, 18,404 +/- 4,040 directly after insulin therapy, and 42,368 +/- 8,517 pmol.min at the 1-year follow-up). At 1 year, seven of the subjects maintained good glycemic control on diet therapy alone, eight required oral hypoglycemic agent (OHA) therapy, and one required insulin therapy. The distinguishing features of those who did not require OHA or insulin therapy were that they required less insulin during the active insulin therapy phase (0.37 +/- 0.05 vs. 0.73 +/- 0.07 units.kg(-1).day(-1)) and were able to attain a lower fasting serum glucose at the end of the period of insulin therapy (5.9 +/- 0.3 vs. 7.7 +/- 0.4 mmol/l).
CONCLUSIONS: These results demonstrate that in newly diagnosed type 2 diabetes with elevated fasting glucose levels, a 2- to 3-week course of intensive insulin therapy can successfully lay a foundation for prolonged good glycemic control. The ease with which normoglycemia is achieved on insulin may predict those patients who can later succeed in controlling glucose levels with attention to diet alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15111515     DOI: 10.2337/diacare.27.5.1028

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  61 in total

1.  Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation.

Authors:  Jinling Hou; Zhao Zhong Chong; Yan Chen Shang; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2010-05       Impact factor: 1.990

2.  Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.

Authors:  Zhimin Huang; Xuesi Wan; Juan Liu; Wanping Deng; Ailing Chen; Liehua Liu; Jianbin Liu; Guohong Wei; Hai Li; Donghong Fang; Yanbing Li
Journal:  Diabetes Technol Ther       Date:  2013-08-30       Impact factor: 6.118

3.  Insulin therapy stimulates lipid synthesis and improves endocrine functions of adipocytes in dietary obese C57BL/6 mice.

Authors:  Xiang Chen; Qiu-qiong Yu; Yan-hua Zhu; Yan Bi; Wei-ping Sun; Hua Liang; Meng-ying Cai; Xiao-ying He; Jian-ping Weng
Journal:  Acta Pharmacol Sin       Date:  2010-02-22       Impact factor: 6.150

4.  Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes.

Authors:  Robert J Romanelli; Sukyung Chung; Jia Pu; Vani Nimbal; Beinan Zhao; Latha Palaniappan
Journal:  Diabetes Res Clin Pract       Date:  2015-01-21       Impact factor: 5.602

Review 5.  Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data.

Authors:  Rebecca J Brown; Kristina I Rother
Journal:  Pediatr Diabetes       Date:  2008-01-24       Impact factor: 4.866

6.  Insulin may have a role to play in protecting beta cells from deterioration in diabetes.

Authors:  A Del Parigi
Journal:  Diabetologia       Date:  2008-04-26       Impact factor: 10.122

7.  [Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes].

Authors:  Edelmiro Menéndez Torre; Francisco Javier Lafita Tejedor; Sara Artola Menéndez; Jesús Millán Núñez-Cortés; Angeles Alonso García; Manuel Puig Domingo; José Ramón García Solans; Fernando Alvarez Guisasola; Javier García Alegría; Javier Mediavilla Bravo; Carlos Miranda Fernández-Santos; Ramón Romero González
Journal:  Aten Primaria       Date:  2011-03-05       Impact factor: 1.137

8.  Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial.

Authors:  Lindsay B Harrison; Beverley Adams-Huet; Xilong Li; Philip Raskin; Ildiko Lingvay
Journal:  J Investig Med       Date:  2014-04       Impact factor: 2.895

9.  Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes.

Authors:  M Shimodaira; Y Muroya; N Kumagai; K Tsuzawa; K Honda
Journal:  J Endocrinol Invest       Date:  2013-04-12       Impact factor: 4.256

Review 10.  Early insulin use in type 2 diabetes: what are the cons?

Authors:  Jean-Louis Chiasson
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.